Equities

Dignitana AB

DIGN:STO

Dignitana AB

Actions
  • Price (SEK)2.00
  • Today's Change0.11 / 5.82%
  • Shares traded388.71k
  • 1 Year change-45.95%
  • Beta1.4360
Data delayed at least 15 minutes, as of May 24 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.

  • Revenue in SEK (TTM)86.06m
  • Net income in SEK-17.36m
  • Incorporated2007
  • Employees27.00
  • Location
    Dignitana ABTraktorgranden 3LUND 226 60SwedenSWE
  • Phone+46 46163090
  • Fax+46 46163099
  • Websitehttps://dignitana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BBS-Bioactive Bone Substitutes Oyj0.00-40.46m88.17m----1.41-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Observe Medical ASA-100.60bn-100.60bn88.24m----0.334----------1.38-----------31.10---51.60--33.76---274.820.0711--0.3526---18.80150.54-93.01--25.73--
Luxbright AB-466.64k-23.07m92.68m----1.97-----0.3717-0.3717-0.00680.5101-0.0103-------50.99-52.69-53.38-60.37-------2,130.96----0.0044--67.10--38.77------
Redsense Medical AB (publ)19.85m-7.57m99.69m5.00--5.01--5.02-0.5389-0.53891.411.420.72614.515.023,970,800.00-27.67-18.66-31.75-20.9950.1169.02-38.11-46.282.21--0.00--74.1128.9448.47---23.62--
ScandiDos AB65.08m-4.85m103.76m34.00--2.40--1.59-0.1063-0.10631.430.75880.95730.47877.39---7.14-13.82-13.39-23.9582.5482.49-7.45-17.090.4511-2.630.00--6.704.01-24.27--4.18--
Ortivus AB78.15m-20.63m116.17m42.00--7.17--1.49-0.4655-0.46551.760.35291.003.364.761,953,650.00-26.44-2.41-51.70-4.6333.8842.46-26.39-1.770.5256--0.4544---19.5510.00-409.66--67.43--
Nanexa AB28.91m-70.62m122.40m19.00--1.32--4.23-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Clinical Laserthermia Systems AB8.27m-79.79m135.63m7.00--2.75--16.39-23.38-23.382.006.290.154310.954.20---150.84-123.49-292.98-312.95-508.29-1,084.16-977.58-1,625.031.50-5.240.0103--31.9935.55-12.92--18.61--
Neola Medical AB0.00-9.04m140.30m7.00--1.83-----0.1536-0.15360.001.090.00----0.00-11.63-17.04-12.52-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
BibbInstruments AB0.00-10.97m145.91m----4.67-----0.4379-0.43790.001.180.00-------32.19-39.57-34.83-42.71--59.36---8,032.40----0.00------2.72---1.94--
Acousort AB5.54m-17.09m151.58m----6.27--27.39-1.23-1.230.40491.620.14575.102.52---44.97-48.62-79.33-69.77-69.83-68.05-308.76-299.582.76--0.00--11.5138.81-24.01------
Dignitana AB86.06m-17.36m152.22m27.00--18.34--1.77-0.2329-0.23291.150.10311.664.3515.073,187,519.00-33.59-42.21-74.20-68.9168.5266.09-20.17-57.290.4633-6.820.7245--17.9020.5922.52---15.31--
Iconovo AB8.47m-42.40m180.67m29.00--1.34--21.33-3.68-3.680.7038.450.0554--1.24292,079.00-27.74-25.43-30.85-28.24234.21134.57-500.63-215.16----0.0666---58.65-9.884.71--34.70--
Arcoma AB171.89m9.40m190.53m31.0020.273.6111.551.110.7130.71313.044.011.813.716.935,544,871.009.921.1218.492.0136.8337.665.470.75680.978811.950.04750.0030.366.4134.81--22.75--
Nexstim Oyj84.16m-15.42m219.24m37.00--6.66--2.60-0.1956-0.19561.090.41920.72110.27083.76195,845.70-13.21-26.77-20.24-43.9096.3892.11-18.32-38.381.42-12.600.61---23.9422.08-201.58--19.51--
Data as of May 24 2024. Currency figures normalised to Dignitana AB's reporting currency: Swedish Krona SEK

Institutional shareholders

15.14%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 29 Feb 20245.42m6.72%
Handelsbanken Fonder ABas of 30 Apr 20244.98m6.18%
FCG Fonder ABas of 30 Jun 20221.80m2.24%
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.